financetom
Business
financetom
/
Business
/
-- Dexterra Group Brief: National Bank Says Co the "Right Choice For Capital Allocation", Adding It "Remains Our Top Pick in 2025"
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
-- Dexterra Group Brief: National Bank Says Co the "Right Choice For Capital Allocation", Adding It "Remains Our Top Pick in 2025"
Aug 6, 2025 12:17 PM

02:47 PM EDT, 08/06/2025 (MT Newswires) --

Price: 9.48, Change: +0.11, Percent Change: +1.17

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Box Reports Mixed Q2 Results With Modest Billings Improvement, RBC Says
Box Reports Mixed Q2 Results With Modest Billings Improvement, RBC Says
Aug 29, 2024
11:12 AM EDT, 08/28/2024 (MT Newswires) -- Box (BOX) reported mixed Q2 results with modest improvements in billings as macro conditions remained stable, RBC Capital Markets said Tuesday in a report. The company reported fiscal Q2 non-GAAP earnings late Tuesday of $0.44 per diluted share on revenue of $270 million. Analysts surveyed by Capital IQ expected EPS of $0.41 on...
Dick's Sporting Goods Likely to Beat Q2 Estimates, Raise Guidance, Wedbush Says
Dick's Sporting Goods Likely to Beat Q2 Estimates, Raise Guidance, Wedbush Says
Aug 29, 2024
11:10 AM EDT, 08/28/2024 (MT Newswires) -- Dick's Sporting Goods' (DKS) fiscal Q2 earnings are expected to top analyst estimates, but a material deceleration in trends in H2 is likely to limit a potential upside for its shares, Wedbush said in a note Wednesday. Growth is being led by the company's mid-upper income customer demographic skew, differentiated and better access...
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
Aug 29, 2024
Thursday, Gain Therapeutics, Inc. ( GANX ) released results from the Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of GT-02287. The company previously announced that no discontinuations or serious adverse events were reported when the study concluded. Also Read: EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson’s Disease. The...
Why Is Polestar Automotive Stock Diving Today?
Why Is Polestar Automotive Stock Diving Today?
Aug 29, 2024
Polestar Automotive Holding UK PLC ( PSNY ) shares are trading lower on Wednesday. The Swedish electric performance car brand disclosed that Michael Lohscheller will become CEO effective October 1, 2024. Lohscheller will succeed Thomas Ingenlath, who is stepping down after successfully positioning the brand for its next phase. Michael Lohscheller has formerly worked as the CEO of Opel, VinFast, and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved